title: Lipid-lowering therapy following major cardiac events: progress and deficits.
abstract: OBJECTIVE
  To assess hospital prescribing of lipid-lowering agents in a tertiary hospital, and examine continuation of, or changes to, such therapy in the 6-18 months following discharge.
  
  
  METHODS
  Retrospective data extraction from the hospital records of patients admitted from October 1998 to April 1999. These patients and their general practitioners were then contacted to obtain information about ongoing management after discharge.
  
  
  METHODS
  Tertiary public hospital and community.
  
  
  METHODS
  352 patients admitted to hospital with acute myocardial infarction or unstable angina, and their GPs.
  
  
  METHODS
  Percentage of eligible patients discharged on lipid-lowering therapy and percentage of patients continuing or starting such therapy 6-18 months after discharge.
  
  
  RESULTS
  10% of inpatients with acute coronary syndromes did not have lipid-level estimations performed or arranged during admission. Documentation of lipid levels in discharge summaries was poor. Eighteen per cent of patients with a total serum cholesterol level greater than 5.5 mmol/L did not receive a discharge prescription for a cholesterol-lowering agent. Compliance with treatment on follow-up was 88% in the group discharged on treatment. However, at follow-up, 70% of patients discharged without therapy had not been commenced on lipid-lowering treatment by their GPs.
  
  
  CONCLUSIONS
  Prescribing of lipid-lowering therapy for secondary prevention following acute coronary syndromes remains suboptimal. Commencing treatment in hospital is likely to result in continuing therapy in the community. Better communication of lipid-level results, treatment and treatment aims between hospitals and GPs might encourage optimal treatment practices.
authors.affiliation: Division of Medicine, Royal Brisbane Hospital, Brisbane, QLD.
authors.forename: A M
authors.initials: AM
authors.lastname: Mudge
authors.forename: R
authors.initials: R
authors.lastname: Brockett
authors.forename: K F
authors.initials: KF
authors.lastname: Foxcroft
authors.forename: C P
authors.initials: CP
authors.lastname: Denaro
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000789:Angina, Unstable / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D004363:Drug Utilization / Q000706:statistics & numerical data; D005194:Family Practice; D005260:Female; D006779:Hospitals, Public; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D010351:Patient Discharge / Q000706:statistics & numerical data; D011793:Queensland; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: D000924:Anticholesteremic Agents; D008055:Lipids; D008077:Lipoproteins, LDL; D002784:Cholesterol